Attainable predictive biomarkers for tumor reaction to mTOR inhibitors, as have been described in glioblastoma, breast and prostate cancer cells, could be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Consequently, this details relies on preclinical assays, based upon in vitro cultured tumor cell lines, which recommend https://lycorine88654.blogdigy.com/the-cpth2-diaries-42546549